Oncolytics: PEI approves continuation of enrollment in Cohort 5 of GOBLET study

Oncolytics (ONCY) Biotech announced that Germany’s medical regulatory body, the Paul-Ehrlich-Institute, has approved the continuation of patient enrollment into Cohort 5 of the GOBLET study. This cohort is evaluating pelareorep in combination with modified FOLFIRINOX with or without atezolizumab in newly diagnosed pancreatic ductal adenocarcinoma patients. Following a positive safety review by the independent Data Safety Monitoring Board, which recommended continuation, the PEI’s approval allows Cohort 5 to progress to full enrollment. Early safety data will be presented at the upcoming 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium later this month, with initial efficacy results expected in the second half of the year.